NAVIGNOSTICS
LIVE

Serial Number

79395780

Owner

Navignostics AG

Attorney

Nicholas D. Wells

Filing Date

Feb 15, 2024

Add to watchlist:

No watchlists yet
View on USPTO

NAVIGNOSTICS Trademark

Serial Number: 79395780 • Registration: 7862453

NAVIGNOSTICS is a trademark filed by Navignostics AG on February 15, 2024. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Navignostics AG (3 trademarks)

c/o Andrea Jacobs,

Entity Type: 25

Andrea Jacobs (2 trademarks)

Zelghalde 8

Entity Type: 98

Trademark Details

Filing Date

February 15, 2024

Registration Date

July 15, 2025

Published for Opposition

May 27, 2025

Goods & Services

Scientific research for medical purposes in the area of cancerous diseases; scientific research in the field of proteomics; oncological research; medical research in the field of oncological diagnostics; computer programming for medical data analysis for cancer diagnostics; development of personalized diagnostics products in the nature of data sampling, imaging and analysis for cancer treatment; software-as-a-service (SaaS) featuring software for use in cancer diagnosis; platform-as-a-service (PaaS) featuring software for use in cancer diagnosis; software-as-a-service (SaaS) featuring software for cell analysis for use in oncology; platform-as-a-service (PaaS) featuring software for cell analysis for use in oncology; software-as-a-service (SaaS) featuring software for medical and scientific research in the field of cancer treatment and diagnosis; platform-as-a-service (PaaS) featuring software for medical and scientific research in the field of cancer treatment and diagnosis; software-as-a-service (SaaS) featuring software using machine learning in the field of medical diagnosis and research, particularly for cancer research, treatment and diagnosis; platform-as-a-service (PaaS) featuring software using machine learning in the field of medical diagnosis and research, particularly for cancer research, treatment and diagnosis; computer programming in the field of using machine learning regarding medical diagnosis and research, particularly for cancer research, treatment and diagnosis; software as a service (SaaS) featuring software for the analysis of medical data, particularly for cancer research, treatment and diagnosis; software-as-a-service (SaaS) featuring software for the analysis of medical data, particularly for cancer research, treatment and diagnosis; platform-as-a-service (PaaS) featuring software for the analysis of medical data, particularly for cancer research, treatment and diagnosis; software as-a-service (SaaS) featuring software for the digital representation of tumours and tumour features; platform-as-a-service (PaaS) featuring software for the digital representation of tumours and tumour features; software as-a-service (SaaS) featuring software for high-resolution digital image representation of the molecular composition of cellular anomalies; platform-as-a-service (PaaS) featuring software for high-resolution digital image representation of the molecular composition of cellular anomalies; software as-a-service (SaaS) featuring software for high-resolution digital image representation of digital tumours; platform-as-a-service (PaaS) featuring software for high-resolution digital image representation of digital tumours; cancer diagnosis research

Reactants for medical diagnosis; diagnostic preparations for medical purposes; diagnostic reagents for medical or veterinary use in in vitro diagnosis; reactants for medical diagnosis, particularly for usage with spatial single-cell proteomics reagents for diagnostic tests for medical use; diagnostic test reagents for veterinary use; diagnostic preparations for medical use; diagnostic radiopharmaceutical preparations for medical purposes; diagnostic substances for medical use; pharmaceutical products, medical and veterinary preparations, namely, pharmaceutical preparations for use in the treatment of cancer; pharmaceuticals for the treatment of cancer; pharmaceutical preparations and compositions for the treatment and prevention of cancer; pharmaceutical preparations for the diagnosis and treatment of cancer; pharmaceutical preparations for the diagnosis of diseases; diagnostic pharmaceutical preparations; pharmaceutical preparations for individual medical diagnosis; medical test kits comprising pharmaceutical preparations for cancer therapy; medical test kits comprising pharmaceutical preparations for use in oncology for cancer screening; medical test kits comprising pharmaceutical preparations for cancer diagnosis; medical test kits comprising pharmaceutical preparations for individual medical diagnosis in the field of protein imaging; diagnostic test kits comprising pathology slides for testing tissue samples; test kits for use in oncology comprising sample tubes for testing tissue samples; diagnostic test kits comprising laboratory equipment for sample preparation, processing and storage for cancer diagnosis; diagnostic test kits for individual medical diagnosis comprising sample collection equipment for tumour analysis

Apparatus for tumour diagnosis, namely, Imaging Mass Cytometry (IMC) apparatus; medical apparatus, namely, spectrometers for machine learning-based spectrum analysis of human blood plasma; Multiplex protein imaging scanners for medical diagnosis; apparatus for clinical diagnosis, namely, digital imaging device; spectrum analysers for use in medical diagnosis; trace material analysers for medical use in diagnosis; apparatus used in implementing diagnosis tests designed to detect abnormal genetic mutations in proteins, namely, spatial proteomics tools; medical test kits for cancer testing; diagnostic, examination, and monitoring equipment, namely, multiplex protein imaging equipment; medical test kits comprising tissue sampling equipment for the use in oncology for cancer screening; medical test kits for cancer diagnosis; medical test kits comprising tissue analysis tools for individual diagnosis in the field of cancer therapy

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Apr 2, 2026 FINO
GENERIC MADRID TRANSACTION SENT TO IB
Feb 6, 2026 XXSS
GENERIC MADRID TRANSACTION CREATED
Feb 5, 2026 XXCR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Oct 31, 2025 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Oct 15, 2025 OPNS
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Oct 15, 2025 FICR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Oct 15, 2025 OPNR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jul 15, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Jul 15, 2025 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 27, 2025 NPUB
PUBLISHED FOR OPPOSITION
May 27, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 21, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 28, 2025 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 24, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 24, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 24, 2025 TROA
REFUSAL PROCESSED BY IB
Oct 12, 2024 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Sep 23, 2024 RFCS
REFUSAL PROCESSED BY MPU
Sep 23, 2024 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Sep 20, 2024 RFCR
NON-FINAL ACTION WRITTEN
Sep 19, 2024 CNRT
ASSIGNED TO EXAMINER
Sep 6, 2024 DOCK
CHANGE OF OWNER RECEIVED FROM IB
Aug 9, 2024 CHLD
APPLICATION FILING RECEIPT MAILED
May 22, 2024 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 22, 2024 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
May 16, 2024 REPR